Ongoing Clinical Trials for Schizophreniform Disorder
There is currently 1 ongoing clinical trial for schizophreniform disorder, also investigating related conditions like schizophrenia and schizoaffective disorder. This trial is exploring intensified medication treatment approaches for patients who have not responded well to their first-line treatment. The study is being conducted across multiple European countries and involves various antipsychotic medications.
Clinical trial locations
- Austria
- Germany
- Italy
- Spain
Study on the Effect of Clozapine and Drug Combination for Patients with Schizophrenia Experiencing First-Line Treatment Failure
This clinical trial is designed for people with schizophreniform disorder, schizophrenia, or schizoaffective disorder who have not responded well to their first medication treatment. The study aims to compare an intensified treatment approach with standard care over a six-week period.
Main inclusion criteria:
- Adults aged 18 to 70 years who can receive treatment as either inpatients or outpatients
- Confirmed diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder
- Currently experiencing first-time treatment failure after at least 4 weeks of initial medication
- Score of 3 or higher on the Clinical Global Impression-Improvement scale, indicating the current treatment is not working effectively
- Specific symptom severity levels measured by the Positive And Negative Syndrome Scale and difficulties in daily functioning
- Women of childbearing age must use effective birth control and have a negative pregnancy test
- Ability to provide written consent, with legal guardian co-signing if necessary
Main exclusion criteria:
- Patients without a confirmed diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder
- Those who have not experienced first-time treatment failure on their initial medication
- Individuals outside the specified age range
- Patients unwilling or unable to follow study procedures
- Members of vulnerable populations not included in the study design
Trial focus: The study investigates whether an intensified medication approach can better reduce symptoms compared to usual treatment for people who have not responded to their first medication. Participants are randomly assigned to either the intensified treatment group or the standard care group. The intensified treatment involves carefully selected and adjusted combinations of antipsychotic medications administered over six weeks. Regular assessments monitor symptom changes, side effects, quality of life, anxiety, and depression levels. The primary measure of effectiveness is the change in symptom severity using the Positive and Negative Syndrome Scale.
Investigational drugs: The trial uses an intensified pharmacological treatment approach involving multiple antipsychotic medications. These include clozapine, ziprasidone, amisulpride, aripiprazole, risperidone, olanzapine, paliperidone, lurasidone, sertindole, brexpiprazole, cariprazine, and asenapine, among others. Additional medications such as fluoxetine hydrochloride, perphenazine, promazine hydrochloride, diazepam, sulpiride, chlorpromazine hydrochloride, fluphenazine decanoate, zuclopenthixol, flupentixol decanoate, haloperidol decanoate, pregabalin, and pyridoxine hydrochloride may also be used. The specific combination, dosage, and administration schedule are determined by the study protocol and carefully monitored by healthcare professionals.
Summary
Currently, there is one active clinical trial addressing schizophreniform disorder and related conditions. This trial is conducted across four European countries: Germany, Austria, Italy, and Spain, providing broad access for patients in these regions. The study focuses on patients who have experienced treatment failure with their initial medication, representing an important research area for improving outcomes in this patient population.
The trial explores an intensified pharmacological approach using multiple antipsychotic medications, including clozapine, which is often considered for treatment-resistant cases. The six-week study period allows researchers to assess whether more aggressive medication strategies can provide better symptom control compared to standard treatment approaches. This research may help inform future treatment guidelines for patients who do not respond adequately to first-line therapies.
